恒瑞医药：注射用SHR-9839等多款药物临床试验获批

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trials - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for several injectable drugs [1] - The approved drugs include SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642 injection, Adalimumab injection, and others, which will undergo clinical trials in the near future [1] - Specifically, a Phase IB/II study will be conducted to evaluate the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor drugs in patients with solid tumors [1]